Edmond de Rothschild Investment Partners disclosed to the public the primary investment of BioDiscovery 4 through its participation in the Series A financing round of Allerca Therapeutics. BioDiscovery 4 invested its fourth fund of Eur5 million or US$6.5million that is dedicated to life sciences. Forbion Capital Partners and EMBL Ventures also participated in the financing round.
The sum of Eur15 million was placed in the Series A capital infusion and would be utilized to sustain the early clinical development of two antibiotic treatments that is intended to fight multi drug resistant gram-negative bacteria.
"Allecra's strategic partnership with Orchid is an innovative collaboration bringing together Allecra's strong development capability with Orchid's track record in antibiotic research and manufacturing. Allecra is supported by a Scientific Advisory Board consisting of world-renowned experts and Allecra's Board of Directors comprises key appointments of entrepreneurs and industrialists with records of success in this area," Olivier Litzka, Partner at Edmond de Rothschild Investment Partners and Board Director at Allecra, commented.
Join the Conversation